Facility expected to generate $5 billion economic impact and 330 jobs.
- UCB selects Georgia for new manufacturing site
- Projected $5 billion economic impact
- Facility to create 330 permanent jobs
UCB has officially selected Georgia as the location for its new biologics manufacturing facility, marking a significant step in the company's production capabilities. This investment is expected to have a substantial economic impact, projected at $5 billion, while creating approximately 330 permanent jobs in the region. This move signals UCB's commitment to advancing its biologics production and supporting local economies.
The new facility will not only contribute to job creation but also enhance the availability of biologic therapies. As a leader in the biopharmaceutical sector, UCB aims to bolster supply and production efficiency through this strategic investment. The choice of Georgia reflects its favorable business climate and expertise in life sciences, making it an ideal location for expansion.
This investment underscores the growing importance of biologics in the healthcare landscape and UCB's role in delivering innovative treatments. By establishing a prominent manufacturing presence in Georgia, UCB will enhance its operational capabilities to better meet patient needs in the future.
